Celsion, Oxford University Using Thermodox and HIFU in Metastatic Liver Cancer Trial

Published:

US biotech Celsion, Inc. will design and conduct a clinical trial in partnership with Oxford University (UK) to evaluate the use of its heat-activated drug, Thermodox, and ultrasound-guided high intensity focused ultrasound in treating patients with metastatic liver cancer. Patient treatments are expected to begin later this year. The study is supported by the National Institute for Health Research Oxford Biomedical Research Centre. It will be conducted as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering and the Oxford University Hospitals NHS Trust.

READ PRESS RELEASE